XIGDUO extended release (XR) Post Marketing Surveillance - XigduoPMS

Exclusion Criteria

• 1. Hypersensitivity to the active substances or to any of the excipients
• 2. Patients with renal impairment (e.g., serum creatinine levels ≥ 1.5 mg/dL for men, ≥ 1.4 mg/dL for women, or creatinine clearance < 60 milliliter(mL)/min or estimated glomerular filtration rate (eGFR)< 60mL/min/1.73 m2) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia.
• 3. Patients with type 1 diabetes mellitus, lactic acidosis, or acute or chronic metabolic acidosis including diabetic ketoacidosis with or without a coma
• 4. Diabetic precoma
• 5. Congestive heart failure that medicinal treatment is required
• 6. Patients with radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials)
• 7. Patients with severe infection or severe traumatism
• 8. In terms of Surgical procedures (except minor procedures not associated with restricted intake of food and fluids)
• 9. Patients with nutrition poor condition, starvation condition, pituitary insufficiency, capsular insufficiency
• 10. Patients with impaired hepatic function (Since impaired hepatic function has been associated with some cases of lactic acidosis, this drug should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.), respiratory failure, acute myocardial infarction, acute or chronic disease causing histotoxic hypoxia like shock, an alcoholic, gastroenteric trouble (anhydremia, diarrhea, vomiting and etc.)
• 11. Pregnant women, women with potential of pregnancy, lactating women
• 12. Patients with hereditary problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.